MetLife, Inc. (MET) Stock Analysis
Latest ClaritX AI analysis ·
MetLife, Inc. operates as a leading global financial services entity, delivering an extensive array of services encompassing insurance, annuities, employee benefits, and asset management. The company manages its operations through five primary divisions: the U.S., Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Holdings. Its broad insurance offerings include life, dental, group short-term and long-term disability, individual disability, pet, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans. MetLife also supports employers with administrative services-only (ASO) arrangements. Furthermore, it provides soph
| Metric | Value |
|---|---|
| Price | $98.33 |
| Market cap | $63.3B |
| Sector | Financial Services |
| Industry | Insurance - Life |
| ClaritX AI score | 90/100 |
| Price/Book | 2.34 |
| Dividend yield | 2.36% |
| Beta | 0.78 |
AI verdict
MetLife, Inc. (MET) represents a premier compounding vehicle operating perfectly at the intersection of deep fundamental undervaluation and generational macroeconomic tailwinds. Generating an astounding $25.42 in free cash flow per share, the enterprise trades at a deeply compressed 3.82x Price-to-Free-Cash-Flow multiple. Operationally, the firm is capitalizing on a rare macro shift; with the 30-year Treasury yield hitting a 19-year high, MetLife is mathematically positioned to reinvest its enormous premium float into highly accretive sovereign debt, locking in expanded net investment spreads for decades. The flawless 5/5 analyst DCF score perfectly corroborates this profound disconnect between intrinsic value and current market pricing, as sell-side analysts recently bumped Q3 EPS estimates to $2.69. Currently trading at $98.33, MetLife sits a mere 2.58% below its absolute 52-week high of $100.93. In highly speculative equities, trading this close to cycle highs can signal dangerous momentum exhaustion. However, MetLife's highly defensive beta of 0.775 entirely alters this risk profile. This low-beta characteristic definitively confirms that the stock's extreme proximity to its highs is rooted in systemic institutional accumulation and bulletproof cash flows, entirely insulated from irrational market euphoria. Supported by a healthy RSI of 56.37, an unwavering base of Q1/Q2 insider accumulation, and a rock-solid 2.41% forward dividend yield, the asset offers an elite combin
What this score has been worth
ClaritX scores MET 90 out of 100 (snapshot 2026-10-21).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 57 analyses that scored in the 90-100 band, the average forward return was +0.4% with a 51% win rate, -4.7pp against the S&P 500. That is a measured tendency across many names, not a forecast for MET — roughly 49% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.